Second Quarter 2026
Filed Aug 6, 2026Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance
Revenue increased 10.0%, net income attributable to the Company increased 46.5%, Adjusted EBITDA increased 22.5%, Free Cash Flow increased 91.6%, and the Company raised its 2026 financial guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $606.0 million | – | 10.0% |
| Net incomeGAAP | $67.3 million | – | 45.7% |
| Net income attributable to the CompanyGAAP | $65.3 million | – | 46.5% |
| Adjusted Net Income Attributable to the Companynon-GAAP | $66.7 million | – | 39.7% |
| Earnings per shareGAAP | $0.51 | – | $0.16 |
| Adjusted Earnings per Sharenon-GAAP | $0.52 | – | $0.15 |
| Adjusted EBITDAnon-GAAP | $140.9 million | – | 22.5% |
| Patient visitsother | 3,610,934 | – | – |
| Visits per dayother | 56,421 visits per day | – | 2.6% |
| Revenue per visitother | $152.67 | – | 4.6% |
| Net cash provided by operating activitiesGAAP | $135.2 million | – | 53.0% |
| Free Cash Flownon-GAAP | $121.0 million | – | 91.6% |
| Capital expendituresother | $15.7 million | – | (37.9%) |
| CashGAAP | $158.0 million | – | – |
| Total debtGAAP | $1,573.6 million | – | – |
| Total assetsGAAP | $3,010.3 million | – | – |
| Net leverage ratioother | 2.99x | – | – |
2026 outlook
- Revenue$2.325 billion to $2.375 billion
- NoteAdjusted EBITDA in the range of $485 million to $495 million
- NoteNet leverage ratio below 3.0x
- NoteFree Cash Flow in the range of $220 million to $240 million
- NoteCapital expenditures in the range of $70 million to $80 million
Capital returns
- Repurchases of approximately 0.4 million shares of common stock totaling $11.0 million
- Cash flow from financing activities used $24.7 million for the quarter, driven primarily by $11.0 million in repurchases of shares of common stock and $8.0 million in dividend payments.
- On August 5, 2026, the Board declared a cash dividend of $0.0625 per share.
- The dividend will be payable on or about August 28, 2026, to stockholders of record as of the close of business on August 20, 2026.
What drove it
- Revenue per visit increased 4.6% from $145.92 in Q2 2025 to $152.67.
- Visits per day increased 2.6% from 55,005 visits per day in Q2 2025 to 56,421 visits per day.
- The increase in year-over-year cash flow from operations was primarily due to an increase in net income from organic growth and through acquisitions and de novos, as well as year-over-year variances in timing associated with payments of current liabilities.
- Concentra opened one de novo occupational health center.
- Total occupational health centers were 633, compared to 628 at the end of Q2 2025, and total onsite health clinics were 415, compared to 406 at the end of Q2 2025.
Concerns
- Total debt was $1,573.6 million as of June 30, 2026.
- There is no assurance that future dividends will be declared.
- The Company expects to announce its chief financial officer succession plan prior to the leadership transition taking effect on November 1, 2026.
- The filing identifies risks including reimbursement increases that may not keep pace with cost inflation, labor shortages and increased labor costs, and changes to workers' compensation fee schedules.
What to watch
- Execution against raised 2026 guidance for revenue, Adjusted EBITDA, Free Cash Flow, capital expenditures and net leverage ratio.
- Whether revenue-per-visit growth and visits-per-day growth continue.
- Progress in de novo center openings, occupational health center growth and onsite health clinic growth.
- The chief financial officer succession-plan announcement and the November 1, 2026 transition of Matt DiCanio to president and chief executive officer and Keith Newton to executive chairman.
Balance sheet and cash flow
- Cash of $158.0 million, total debt of $1,573.6 million and total assets of $3,010.3 million as of June 30, 2026.
- Net leverage ratio of 2.99x as of June 30, 2026, which was in compliance with the financial covenant under the credit agreement.
- Cash flow from investing activities resulted in cash used of $14.2 million, including capital expenditures of $15.7 million, partially offset by proceeds from sale of assets of $1.5 million.
- Net increase in cash of $96.3 million for the quarter.
Analysis
Concentra reported a strong second quarter, with revenue of $606.0 million, up 10.0% from $550.8 million in Q2 2025. The top-line gain combined higher activity and pricing or mix indicators: visits per day increased 2.6% to 56,421 visits per day, while revenue per visit increased 4.6% to $152.67. The Company also expanded its footprint to 633 occupational health centers and 415 onsite health clinics, including one de novo occupational health center in the quarter.
Profit growth outpaced revenue growth. Net income increased 45.7% to $67.3 million, net income attributable to the Company increased 46.5% to $65.3 million, and Adjusted EBITDA increased 22.5% to $140.9 million. Adjusted Net Income Attributable to the Company increased 39.7% to $66.7 million. Earnings per share were $0.51, while Adjusted Earnings per Share were $0.52, with the release reporting increases of $0.16 and $0.15 over the prior year, respectively.
Cash generation strengthened materially. Net cash provided by operating activities rose 53.0% to $135.2 million, and Free Cash Flow rose 91.6% to $121.0 million. The Company attributed the operating-cash-flow increase primarily to higher net income from organic growth, acquisitions and de novos, as well as timing variances in payments of current liabilities. Capital expenditures declined 37.9% to $15.7 million, which also supported Free Cash Flow. The balance sheet carried $158.0 million of cash and $1,573.6 million of total debt, with a 2.99x net leverage ratio that was in compliance with the credit agreement covenant.
Capital allocation included $11.0 million of common-stock repurchases and $8.0 million in dividend payments during the quarter. The Board subsequently declared a cash dividend of $0.0625 per share. Management raised 2026 guidance, now calling for revenue of $2.325 billion to $2.375 billion, Adjusted EBITDA of $485 million to $495 million, Free Cash Flow of $220 million to $240 million, capital expenditures of $70 million to $80 million, and a net leverage ratio below 3.0x.
The quarter also introduced a planned leadership transition effective November 1, 2026. Matt DiCanio will become president and chief executive officer, while Keith Newton will become executive chairman. The Company expects to announce its chief financial officer succession plan before that transition. Key execution points are sustaining revenue-per-visit and visit-volume growth, converting operating performance into Free Cash Flow while funding expansion, maintaining leverage below the guided threshold, and managing the leadership transition.
Management, verbatim
Leading Concentra and our dedicated colleagues over the last decade has been a tremendous privilege, and I am proud of what we have built together a leader in occupational health. Our momentum reflects clear priorities and a team committed to delivering results. Matt has been instrumental in shaping that strategy and driving Concentra’s performance, making this the right time to transition leadership.
Keith Newton, chief executive officer
Our strong performance reflects the strength of our strategy, our operating model and our people. As CEO, my priorities are to: deliver high-quality care, create meaningful value for customers and patients, and pursue disciplined growth. As Concentra approaches its 50th year, our experienced leadership team, operating leverage, and steadfast commitment to our mission position us well for continued growth.
Matt DiCanio, president and chief financial officer
Matt has played a pivotal role in shaping Concentra’s strategy, performance, and growth. His extensive knowledge of the business, proven leadership, and commitment to Concentra’s mission and culture make him the right leader to guide the Company as it approaches its 50th year and builds for the future.
Robert Ortenzio, chairman of the Board
Not in the filing
stated, not guessed- Segment revenue, segment comparisons and segment-level drivers were not provided.
- Gross profit, gross margin, operating income, operating margin, operating expenses and tax rate were not provided.
- Prior-year values for net income attributable to the Company, Adjusted Net Income Attributable to the Company, earnings per share and Adjusted Earnings per Share were not provided.
- Prior-quarter comparisons for reported metrics were not provided.
- Diluted weighted-average shares outstanding were not provided.
- Prior-period cash, debt, total assets and net leverage ratio were not provided.
- Previous-release outlook was not provided, so comparisons of actual results with prior guidance cannot be made.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.